Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

Revefenacin, a long-acting muscarinic antagonist for nebulization, has been shown to improve lung function in patients with chronic obstructive pulmonary disease. Here we report pharmacokinetic (PK) and safety results from two multicenter, open-label, single-dose trials evaluating revefenacin in subjects with severe renal impairment (NCT02578082) and moderate hepatic impairment (NCT02581592). The renal impairment trial enrolled subjects with normal renal function and severe renal impairment (estimated glomerular filtration rate